Inhibrx Biosciences, Inc. (INBX) stock
INBXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$74.18−3.48 (-4.48%)
Close on Nov 17, 2026Market cap $1.09BP/E –Yield –
Inhibrx Biosciences r&d expenses
Research and development expenses are spending on new products and technology.
Inhibrx Biosciences's R&D Expenses for the twelve months ending Sep 30, 2026 was $100.43M, down 17.0% year over year. For fiscal 2025 it was $113.03M, down 44.5% from the year before. The highest annual figure on record is $203.74M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $113.03M | -44.5% |
| FY2024 | Dec 31, 2024 | $203.74M | +6.3% |
| FY2023 | Dec 31, 2023 | $191.64M | +73.9% |
| FY2022 | Dec 31, 2022 | $110.19M | +54.2% |
| FY2021 | Dec 31, 2021 | $71.44M | -2.8% |
| FY2020 | Dec 31, 2020 | $73.50M | +53.4% |
| FY2019 | Dec 31, 2019 | $47.91M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $25.97M | -9.0% |
| Q2 FY2026 | Jun 30, 2026 | $23.90M | +7.3% |
| Q1 FY2026 | Mar 31, 2026 | $25.22M | -31.6% |
| Q4 FY2025 | Dec 31, 2025 | $25.35M | -24.0% |
| Q3 FY2025 | Sep 30, 2025 | $28.54M | -26.6% |
| Q2 FY2025 | Jun 30, 2025 | $22.27M | -67.1% |
| Q1 FY2025 | Mar 31, 2025 | $36.88M | -42.2% |
| Q4 FY2024 | Dec 31, 2024 | $33.37M | -59.4% |
| Q3 FY2024 | Sep 30, 2024 | $38.89M | +2.2% |
| Q2 FY2024 | Jun 30, 2024 | $67.63M | +98.3% |
| Q1 FY2024 | Mar 31, 2024 | $63.85M | +70.8% |
| Q4 FY2023 | Dec 31, 2023 | $82.09M | +169.6% |
| Q3 FY2023 | Sep 30, 2023 | $38.06M | +52.6% |
| Q2 FY2023 | Jun 30, 2023 | $34.11M | +14.0% |
| Q1 FY2023 | Mar 31, 2023 | $37.39M | +50.2% |
| Q4 FY2022 | Dec 31, 2022 | $30.45M | +63.6% |
| Q3 FY2022 | Sep 30, 2022 | $24.93M | +34.9% |
| Q2 FY2022 | Jun 30, 2022 | $29.91M | +67.1% |
| Q1 FY2022 | Mar 31, 2022 | $24.90M | +51.4% |
| Q4 FY2021 | Dec 31, 2021 | $18.62M | +5.4% |
| Q3 FY2021 | Sep 30, 2021 | $18.49M | -6.8% |
| Q2 FY2021 | Jun 30, 2021 | $17.90M | -5.6% |
| Q1 FY2021 | Mar 31, 2021 | $16.44M | -3.4% |
| Q4 FY2020 | Dec 31, 2020 | $17.67M | +43.8% |
| Q3 FY2020 | Sep 30, 2020 | $19.84M | +55.2% |
| Q2 FY2020 | Jun 30, 2020 | $18.97M | – |
| Q1 FY2020 | Mar 31, 2020 | $17.02M | – |
| Q4 FY2019 | Dec 31, 2019 | $12.28M | – |
| Q3 FY2019 | Sep 30, 2019 | $12.79M | – |
See a number that looks wrong?